Katrina S. Pedersen

Also affiliated with Mayo Clinic in Arizona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial”.

MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial

International Journal of Radiation Oncology*Biology*Physics(2022)10.1016/j.ijrobp.2022.07.015

N/A

0.406DataRank · unranked

14 citations

Jeffrey R. Olsen, Olga L. Green, R Chin, William G. Hawkins, Ryan C. Fields +16 more

Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers

Hepatology Communications(2022)10.1002/hep4.2073

N/A

0DataRank · unranked

23 citations

Xiaoyu Zong, Mengyao Shi, Cassandra Fritz, Katrina S. Pedersen, Linda R. Peterson +5 more

Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps643

N/A

0DataRank · unranked

2 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Shay Bellasea +2 more

Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4146

N/A

0DataRank · unranked

1 citations

Kian-Huat Lim, Robert R. McWilliams, Rama Suresh, A. Craig Lockhart, Amberly Brown +15 more

Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps784

N/A

0DataRank · unranked

1 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby +7 more